Lilly Corporate Center
Indianapolis , IN 46285
Indianapolis , IN 46285
News
-
Point Biopharma Inc soared 84% to $12.23 after the company agreed to be acquired by Eli Lilly for $12.50 a share in cash or $1.4 billion.
Eli Lilly & Company decreased 1.1% to $532.39.
Oct 3, 2023
Executive/
Director
Links
Price
- Last Close
-
$ 782.22
$ +4.27 0.55 %
Jan 3, 2025
- 52-Week High/Low
- $955.07 - $525.1
- YTD
- 1.3%
- Trading Volume
- 58,448
- Market Cap Full
- $ 742.6B
- Shares Outstanding
-
949.3M
Oct 30, 2023
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | -14% | 15.1% | -7.7% | 12.1% | -5% | 11.4% | 3.7% | -6.2% | 33.2% | 1.3% |
| Q2 | 10.1% | -1.5% | 13.5% | -14.3% | 4% | 23.5% | 13.2% | 36.4% | 19.5% | - |
| Q3 | 2.6% | 4.6% | 25.7% | 1% | 8% | 0.7% | -0.6% | 14.6% | 16.3% | - |
| Q4 | -7.8% | -1.6% | 8.1% | 16.6% | 14.3% | 19.6% | 13.5% | 8.5% | -0.4% | - |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 1.3% | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | 10.5% | 16.8% | 3.2% | -6.7% | 13.1% | 10.9% | -11.1% | 16.3% | - | - | - | -2.8% |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25% | -10% | 18% | 40% | 13% | 27% | 66% | 32% | 60% | 32% | 1% |
Earnings
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Q1 | 0.83 | 0.98 | 1.16 | 4.31 | 1.6 | 1.49 | 2.1 | 1.49 |
| Q2 | 0.86 | 1.11 | -0.25 | 1.44 | 1.55 | 1.53 | 1.05 | 1.95 |
| Q3 | 0.88 | 1.05 | 1.12 | 1.37 | 1.33 | 1.22 | 1.61 | -0.06 |
| Q4 | 0.95 | 1.14 | 1.1 | 1.64 | 2.31 | 1.9 | 2.14 | - |
| A | 3.5 | 4.3 | 3.1 | 8.9 | 6.8 | 6.1 | 6.9 | 3.38 |
Annual Returns
52 Week
High/Low
Annual
Earnings
Chart
Trading Volume
Dividend +
Dividend +
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Q1 | 0.74 | 0.85 | 0.98 | 1.13 | 1.30 | 1.50 |
| Q2 | 0.74 | 0.85 | 0.98 | 1.13 | 1.30 | - |
| Q3 | 0.74 | 0.85 | 0.98 | 1.13 | 1.30 | - |
| Q4 | 0.74 | 0.85 | 0.98 | 1.13 | 1.30 | - |
| A | 2.96 | 3.4 | 3.92 | 4.52 | 5.2 | 1.5 |
Outstanding Shares
(In Millions) +
Jan 16, 2024
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Mar | - | 1035.4 | 956.4 | 958.4 | 952.3 | 950.3 |
| Jun | 1085.4 | 970.8 | 956.5 | 959 | 950.2 | 949.3 |
| Sep | 1074 | 965.4 | 956.5 | 956.6 | 950.2 | 949.3 |
| Dec | 1059.3 | 960.1 | 956.6 | 956.6 | 950.2 | 949.3 |
SEC Filings
Financial Ratios
| 2022 | 2021 | 2020 | 2019 | 2018 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Management | ||||||||||||||||||
| Inventory / Stock Turnover | 1.5 | 1.9 | 1.4 | 1.5 | 1.6 | |||||||||||||
| Fixed Asset Turnover | 1.6 | 1.7 | 1.6 | 1.8 | 1.9 | |||||||||||||
| Total Asset Turnover | 0.6 | 0.6 | 0.5 | 0.6 | 0.6 | |||||||||||||
| Leverage | ||||||||||||||||||
| Debt Ratio | 0.8 | 0.8 | 1 | 1 | 0.6 | |||||||||||||
| Debt – Equity Ratio | 1.4 | 1.7 | 2.9 | 5.1 | 1.1 | |||||||||||||
| Interest Coverage | 8.1 | 8.2 | -44.5 | -1.5 | 7.6 | |||||||||||||
| Equity multiplier | 1.6 | 1.8 | 2.6 | 4.5 | 1.2 | |||||||||||||